H.C. Wainwright analyst Joseph Pantginis noted that a "very simple, but incredibly important tweak" was made in the protocol of Onconova's oral rigosertib and azacitidine combination study in MDS patients which the firm believes could lead to "longer duration of therapy without dose interruptions or reductions with potential added clinical benefit to patients." Pantginis reiterated a Buy rating and $7.50 price target on Onconova shares, although he did note there was a risk the company would be unable to find financing to progress its drugs through a Phase 3 study.